These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2008-000513-29 Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dactyli... 2009-12-02 due-trials
Completed, but no date, and reported results 2010-022083-12 Evaluation of tolerability and efficacy of subcutaneous cluster-immunotherapy in patients with allergic rhinitis / rhino-conjunctivitis due to grass pollen bad-data
Not reported 2011-002296-42 Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy 2022-09-29 due-trials
Ongoing 2011-002301-29 PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM GRASS POLLEN ALLERGY Estudio de fase II para evaluar la tolerabilidad, segurida... not-yet-due
Ongoing 2011-002317-10 Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy not-yet-due
Ongoing 2011-002319-27 Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from birch pollen allergy not-yet-due
Ongoing 2011-002321-22 PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM HOUSE DUST MITE ALLERGY Estudio de fase II para evaluar la tolerabilidad, segur... not-yet-due
Ongoing 2021-002881-42 Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergy not-yet-due
Ongoing 2021-005169-41 Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy not-yet-due
Ongoing 2021-006533-19 Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy not-yet-due
Ongoing 2022-001587-97 Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy not-yet-due
Ongoing 2022-001610-19 Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy not-yet-due